Key result
Gemfibrozil improves lipid profiles and fibrinolytic activity versus placebo, linking higher HDL to increased t-PA.
Why the study?
The effects of gemfibrozil on fibrinolysis and plasma lipoprotein levels in patients with primary hypertriglyceridemia were investigated to understand its role beyond lipid regulation.
Does gemfibrozil 600 mg b.i.d. improve lipid profiles and fibrinolytic parameters in patients with primary hypertriglyceridemia?
RCT (n=20)
Double-blind
Randomized
Does gemfibrozil 600 mg b.i.d. improve lipid profiles and fibrinolytic parameters in patients with primary hypertriglyceridemia?
Gemfibrozil improves both lipid profiles and fibrinolytic system parameters in patients with primary hypertriglyceridemia.
Answers are grounded in this paper and cite their sources.
Supports gemfibrozil for dual lipid-fibrinolytic benefits in hypertriglyceridemia; confirms lipid effects while extending evidence to hemostatic parameters.
A randomized double-blind study was carried out with gemfibrozil (600 mg b.i.d.) vs placebo in 20 patients (twelve males and eight females, age 52 +/- 3 years, BMI 24.2 +/- 0.4) suffering from primary hypertriglyceridemia (Fredrickson's type IV). Each group was treated for a 12 week period with gemfibrozil (n = 10) or placebo (n = 10) patients) in a double-blind fashion. Total cholesterol, HDL-cholesterol (HDL-C) and its subfractions (HDL2-C and HDL3-C), blood glucose, Apolipoproteins A1 and B, fibrinogen, plasminogen, factor VII, t-PA:Ag and PAI activity pre- and post-venous occlusion (VO) were determined. In the gemfibrozil-treated group a significant decrease of total cholesterol and triglycerides and a significant increase of HDL-C and HDL2-C were found. During gemfibrozil treatment a significant reduction of factor VII, fibrinogen and plasminogen levels was also observed. After 12 weeks of treatment in the gemfibrozil group the release of t-PA:Ag in response to venous occlusion was significantly higher and plasma PAI activity was significantly lower than in placebo group. Moreover positive correlations between HDL cholesterol and t-PA:Ag post-VO (r = 0.56, P < 0.01) and between HDL2-C cholesterol and t-PA:Ag post-VO (r = 0.59, P < 0.01) and a negative correlation between triglycerides and t-PA:Ag post-VO (r = -0.65, P < 0.01) were found. The data obtained suggest that gemfibrozil, in addition to the well established lipid-regulating effect, appears to have a positive role in the regulation of reverse cholesterol transport and fibrinolytic system.
No takes yet. Share an insight, caveat, or question.
Avellone et al. (1995) conducted an RCT in Primary hypertriglyceridemia (Fredrickson's type IV) (n=20). Gemfibrozil vs. Placebo was evaluated on Lipid levels and fibrinolytic parameters. Gemfibrozil improved lipid profiles and fibrinolytic activity compared to placebo, with a positive correlation between HDL cholesterol and t-PA:Ag post-venous occlusion.
Synapse has enriched 10 related papers. Consider them for comparative context: